Clearmind Medicine

Clearmind Medicine is a Vancouver, Canada-based clinical-stage pharmaceutical company developing novel, non-hallucinogenic neuroplastogen-derived therapies for alcohol use disorder, binge drinking, obesity and metabolic syndrome, and other underserved conditions. Its lead program, CMND-100 (MEAI-based), is in a Phase IIa alcohol-use-disorder trial — one-third of Part C enrolled as of September 1, 2026 — with earlier-stage work spanning an intranasal MEAI formulation and MDMA-related IP for PTSD; development collaborations include SciSparc, Yissum Research Development Company of the Hebrew University of Jerusalem, Polyrizon, and NeuroThera Labs. On September 4, 2026 the company signed a definitive agreement to acquire a 51% stake in an EV wireless-charging company serving automated parking and robotaxis — a diversifying transaction that triggered a sharp single-session selloff (-31.8%).